LCN2 and acute kidney injury: Furthermore, several emerging AKI biomarkers, including tissue inhibitor of metalloproteinases-2 and insulin-like growth factor binding protein-7 (TIMP-2 × IGFBP-7), interleukin-18 (IL-18), and plasma NGAL, have been shown to predict the progression of AKI [19–21].